Physician profile
Tom Longest
NPI 1851477079
$1,670.09
in general payments reported to CMS, 2019-2025
18 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $131 · 2020: $685 · 2021: $543 · 2022: $152 · 2023: $121 · 2024: $38.46.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $159.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $159.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $395.10 | 2020-2023 | Jardiance |
| Janssen Pharmaceuticals, INC | $235.15 | 2019-2021 | |
| Pfizer INC. | $143.99 | 2020-2023 | |
| Astrazeneca Pharmaceuticals Lp | $129.33 | 2019-2023 | Farxiga |
| Abbvie INC. | $113.93 | 2021-2024 | |
| Lilly USA, LLC | $92.94 | 2020-2023 | Jardiance |
| Astellas Pharma US INC | $89.00 | 2021 | |
| Amarin Pharma, INC. | $82.45 | 2020-2021 | |
| Novo Nordisk INC | $82.35 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $76.55 | 2019-2021 | |
| Sunovion Pharmaceuticals INC. | $68.21 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $40.34 | 2020-2024 | Xifaxan |
| Esperion Therapeutics, INC. | $29.25 | 2020-2021 | |
| Allergan, INC. | $28.52 | 2020 | |
| Xeris Pharmaceuticals, INC. | $17.82 | 2023 | Gvoke Hypopen |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $16.54 | 2020 | |
| Novartis Pharmaceuticals Corporation | $15.35 | 2021 | |
| Biogen, INC. | $13.27 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tom Longest listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.